Program
cagrilintide
Also written as “Cagrilintide”, “NNC0174-0833” and “CagriSema”.
In Novo Nordisk's own words, CagriSema is a fixed-dose combination of a long-acting amylin analog, cagrilintide and a GLP-1 receptor agonist, semaglutide.
. Its studies are mostly in Obesity · Diabetes Mellitus, Type 2 · Hypertension · Renal Insufficiency, Chronic · Cardiovascular Diseases, led by Novo Nordisk.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novo Nordisk | 5018 open or running | phase 3since May 24, 2022 | Nov 21, 2014 | Mar 1, 2027phase 3 · NCT07011667 |
- Named in Novo Nordisk’s own pipeline as
Cagrilintide
, phase 3, as of Nov 5, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 32 studies since Nov 21, 2014.
- May 30, 2025Phase 1 study in ObesityNCT07010432 · 144 planned · Denmark
- Jun 1, 2025Phase 3 study in ObesityNCT07011667 · 609 enrolled · United States
- Sep 13, 2025Phase 1 study in ObesityNCT07184086 · 80 enrolled · United States
- Oct 23, 20252 phase 3 studiesNCT07220759, NCT07220642
- Nov 19, 2025Phase 3 study in OverweightNCT07253285 · 460 planned · United States, Australia, Austria and more
- Dec 5, 2025Phase 3 study in Diabetes Mellitus, Type 2NCT07282613 · 80 planned · United States, Argentina, Brazil and more
- Jan 21, 2026Phase 3 study in OverweightNCT07357766 · United States, Bulgaria, Denmark and more
- Jan 21, 2026Phase 2 study in Diabetes Mellitus, Type 2NCT07357740 · United States, Denmark, Greece and more
- Apr 7, 20263 phase 1 studiesNCT07527195, NCT07597018, NCT07557953
- Apr 27, 2026Phase 3 study in ObesityNCT07564414 · 2,500 planned · United States, Argentina, Australia and more
- May 17, 20262 phase 1 studiesNCT07605052, NCT07607587
- Jul 30, 2026Phase 3 study in OverweightNCT07745504 · 285 planned · United States, Greece, Hungary and more
- Sep 8, 2026Phase 3 study in Diabetes Mellitus, Type 2NCT07817251 · 210 planned · United States
- Oct 30, 2026Phase 3 study in HypertensionNCT07919405 · 1,408 planned · United States, Argentina, Australia and more
Ahead
- Mar 1, 2027Primary completion: phase 3 study in ObesityNCT07011667
- Apr 13, 2027Primary completion: phase 1 study in OverweightNCT07557953
- May 11, 2027Primary completion: phase 3 study in ObesityNCT07220642
- May 12, 2027Primary completion: phase 3 study in OverweightNCT07220759
TargetBeta
“CagriSema is a fixed-dose combination of a long-acting amylin analog, cagrilintide and a GLP-1 receptor agonist, semaglutide.”company, read by Claude · source
Other programs on CALCR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| zenagamtide | Novo Nordisk | phase 3 | 35 |
| petrelintiderule | Zealand Pharma | phase 3 | 11 |
| ABBV-295 | AbbVie | phase 2 | 5 |
| PF-08653945 | Pfizer | phase 2 | 2 |
| GUB014295 | AbbVie | phase 1 | 1 |
| CagriSema A | Novo Nordisk | phase 1 | 1 |
Studies
All 50 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07919405Hypertension · United States, Argentina, Australia and more | 3 | Not yet recruiting | Jun 1, 2028 | 1,408 |
| NCT07817251Diabetes Mellitus, Type 2 · United States | 3 | Recruiting | Jun 9, 2027 | 210 |
| NCT07745504Overweight · United States, Greece, Hungary and more | 3 | Recruiting | May 18, 2027 | 285 |
| NCT07607587Obesity · United States | 1 | Recruiting | Nov 19, 2027 | 114 |
| NCT07605052Overweight · United States | 1 | Completed | Aug 19, 2026 | 50 |
| NCT07564414Obesity · United States, Argentina, Australia and more | 3 | Recruiting | Feb 23, 2028 | 2,500 |
| NCT07557953Overweight · Germany | 1 | Recruiting | Apr 13, 2027 | 120 |
| NCT07597018Obesity · Germany | 1 | Recruiting | May 28, 2027 | 234 |
| NCT07527195Obesity · Denmark | 1 | Recruiting | Apr 28, 2028 | 100 |
| NCT07357766Overweight · United States, Bulgaria, Denmark and more | 3 | Withdrawn | Nov 29, 2027 | 0 |
| NCT07357740Diabetes Mellitus, Type 2 · United States, Denmark, Greece and more | 2 | Withdrawn | Aug 25, 2027 | 0 |
| NCT07282613Diabetes Mellitus, Type 2 · United States, Argentina, Brazil and more | 3 | Recruiting | Sep 7, 2029 | 80 |
| NCT07253285Overweight · United States, Australia, Austria and more | 3 | Recruiting | Mar 20, 2030 | 460 |
| NCT07220759Overweight · United States, Argentina, Canada and more | 3 | Active, not recruiting | May 12, 2027 | 330 |
| NCT07220642Obesity · United States, Argentina, Australia and more | 3 | Active, not recruiting | May 11, 2027 | 300 |
| NCT07184086Obesity · United States | 1 | Active, not recruiting | Oct 12, 2027 | 80 |
| NCT07011667Obesity · United States | 3 | Active, not recruiting | Mar 1, 2027 | 609 |
| NCT07010432Obesity · Denmark | 1 | Recruiting | May 3, 2028 | 144 |
| NCT06797869Diabetes Mellitus, Type 2 · United States, Canada, Denmark and more | 2 | Completed | Jun 26, 2026 | 142 |
| NCT06780449Obesity · United States, Belgium, Canada and more | 3 | Active, not recruiting | Aug 28, 2028 | 400 |
| NCT06716307Obesity · United States | 1 | Completed | Mar 28, 2025 | 18 |
| NCT06534411Diabetes Mellitus, Type 2 · United States, Argentina, Australia and more | 3 | Completed | Jun 2, 2026 | 1,023 |
| NCT06409130Alcohol-related Liver Disease · United States, Australia, Bulgaria and more | 2 | Completed | Nov 21, 2025 | 270 |
| NCT06403761Diabetes Mellitus, Type 2 · Germany | 1 | Completed | Dec 28, 2025 | 158 |
| NCT06388187Obesity · United States, Canada, France and more | 3 | Completed | Apr 22, 2026 | 300 |
| NCT06323174Diabetes Mellitus, Type 2 · United States, China, Hungary and more | 3 | Completed | Oct 1, 2025 | 189 |
| NCT06323161Diabetes Mellitus, Type 2 · United States, China, Japan and more | 3 | Completed | Sep 9, 2025 | 274 |
| NCT06289504Obesity · Canada | 1 | Completed | Oct 16, 2024 | 34 |
| NCT06267092Overweight · Germany | 1 | Completed | Apr 7, 2025 | 164 |
| NCT06221969Diabetes Mellitus, Type 2 · United States, Argentina, Australia and more | 3 | Completed | Mar 4, 2026 | 1,024 |
| NCT06207877Obesity · Germany | 1 | Completed | Oct 16, 2024 | 62 |
| NCT06131437Obesity · United States | 3 | Completed | Dec 8, 2025 | 809 |
| NCT06131372Renal Insufficiency, Chronic · United States, Argentina, Brazil and more | 2 | Completed | Sep 24, 2025 | 626 |
| NCT06065540Diabetes Mellitus, Type 2 · United States, Argentina, Australia and more | 3 | Completed | Nov 19, 2025 | 2,734 |
| NCT05996848Obesity · China | 3 | Completed | Jan 6, 2025 | 300 |
| NCT05813925Obesity · Japan, Taiwan | 3 | Completed | Jan 17, 2025 | 331 |
| NCT05804162Obesity · Germany | 1 | Completed | Aug 12, 2023 | 107 |
| NCT05669755Cardiovascular Diseases · United States, Argentina, Australia and more | 3 | Active, not recruiting | Sep 1, 2027 | 7,101 |
| NCT05567796Obesity · United States, Argentina, Australia and more | 3 | Active, not recruiting | Oct 30, 2024 | 3,400 |
| NCT05564104Hepatic Impairment · Czechia, Germany, Slovakia | 1 | Completed | Sep 6, 2024 | 32 |
| NCT05394519Overweight · United States, Austria, Canada and more | 3 | Completed | Jan 28, 2025 | 1,200 |
| NCT04982575Diabetes Mellitus, Type 2 · United States | 2 | Completed | Jul 7, 2022 | 92 |
| NCT04940078Obesity · Canada, Denmark | 1 | Completed | Jan 19, 2022 | 40 |
| NCT04209049Overweight · United States | 1 | Completed | Jan 5, 2021 | 33 |
| NCT04074174Overweight · Canada | 1 | Completed | Mar 6, 2020 | 31 |
| NCT03856047Overweight · United States, Canada, Denmark and more | 2 | Completed | Mar 2, 2020 | 706 |
| NCT03787225Obesity · United States | 1 | Completed | Jun 4, 2019 | 66 |
| NCT03600480Obesity · United States | 1 | Completed | Jun 12, 2020 | 96 |
| NCT02958085Nutrition Disorders · United States | 1 | Completed | Jan 24, 2018 | 96 |
| NCT02300844Nutrition Disorders · United States | 1 | Completed | Mar 21, 2016 | 54 |
How it is read
Names in the registry
- “Cagrilintide”, 29 entries
- “NNC0174-0833”, 7 entries
- “CagriSema”, 3 entries
- “CagriSema (Cagrilintide B and Semaglutide I)”, 3 entries
- “Cagrisema”, 2 entries
Conditions, from the studies’ own filings
- Obesity, 34 studies
- Diabetes Mellitus, Type 2, 11 studies
- Hypertension, 1 study
- Renal Insufficiency, Chronic, 1 study
- Cardiovascular Diseases, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.